Patent EP0331939A2 successfully refreshed from Google Patents.
EP0331939A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method and compositions for conferring resistance to retroviral infection
Assignee: Greatbatch Gen-Aid Ltd
•
Filing: 1989-02-16
•
Granted: —
•
Expires: 2009-02-16
Abstract
Abstract In accordance with the present invention, a method of conferring resistance to retroviral infection upon a host cell is disclosed. The method involves transforming the host cell with a vector comprising a polynucleotide directing transcription within the host cell of RNA which (a) is complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus, and (b) is effective to inhibit replication of the retrovirus when the host cell is infected. A method of treatment using cells upon which resistance to infection has been conferred is also disclosed. Nucleic acid constructs including a polynucleotide as previously described are also disclosed. The construct can include a vector as previously described. Cells upon which resistance to infection has been conferred by the above-described methods and their progeny are also disclosed. The progeny of the originally transformed cells "contain a sequence which is descendant from" the polynucleotide previously described. RNA molecules directed by the polynucleotide are also disclosed. Such molecules are (a) being complementary or homologous to a nucleic acid sequence within the genome of a retrovirus, and (b) being effective to inhibit replication of said retrovirus. Finally, conferring resistance to infection by the above-discribed methods using a synthetic polynucleotide which is complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of the retrovirus and is effective to inhibit replication of said retrovirus.
Inventors
- 👤 Wilson Greatbatch
- 👤 John C. Sanford
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 02:04
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; C07; C07K; C07K14/00; C07K14/005; C12N15/1132; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K48/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13022; C12N2740/13041; C12N2740/13043; C12N2740/15011; C12N2740/15022; C12N2740/16011; C12N2740/16041; C12N2740/16043
Claims Analysis
Total Claims: 54
Claim 1
Independent Claim
67 words
A method of conferring resistance to retrovirus infection upon a host cell, said method comprising: transforming said host cell with a vector comprising a polynucleotide directing transcription within said host cell of RNA which (a) is complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) is effective to inhibit replication of said retrovirus.
Claim 2
Independent Claim
67 words
A method of conferring resistance to retrovirus infection upon a host cell, said method comprising: transforming said host cell with a vector comprising a polynucleotide directing transcription within said host cell of RNA which (a) is complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) is effective to inhibit replication of said retrovirus.
Claim 3
Dependent Claim
59 words
The method according to claim 1, said method comprising transforming said host cell with a vector comprising a polynucleotide directing transcription within said host cell of RNA which (a) is homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) is effective to inhibit replication of said retrovirus.
Claim 4
Independent Claim
101 words
A method according to any of claims 1 or 2, said method comprising transforming said host cell with a vector comprising a polynucleotide directing transcription within said host cell of RNA which (a) is complementary or homologous to a nucleic acid sequence within one or more regions within the genome of said retrovirus selected from the group consisting of LTR region, the U5 region, the U3 region, the R region, the PBS region, the AUG start codon region, the polyP region, the cap site, the leader region and RNA splice sites, and (b) is effective to inhibit replication of said retrovirus.
Claim 5
Independent Claim
19 words
The method of any of claims 1 to 3, wherein said gene coding regions code for a viral protein.
Claim 6
Dependent Claim
34 words
The method of claim 4, wherein said gene coding region is selected from the group consisting of the ENV protein, the POL protein, the GAG protein, the ART protein and the TAT protein region.
Claim 7
Dependent Claim
18 words
The method according to claim 5, wherein said TAT protein is modified to act as a viral repressor.
Claim 8
Dependent Claim
24 words
The method according to claim 6, wherein said TAT protein is modified by preserving its nucleic acid binding function and inhibiting its activator functions.
Claim 9
Dependent Claim
18 words
The method according to claim 5, wherein said ART protein is modified to act as a viral repressor.
Claim 10
Dependent Claim
24 words
A method according to claim 8, wherein said ART protein is modified by preserving its nucleic acid binding function and inhibiting its activator functions.
Claim 11
Independent Claim
17 words
The method according to any of claims 1 to 9, wherein said polynucleotide is a synthetic polynucleotide.
Claim 12
Independent Claim
15 words
The method according to any of claims 1 to 10, wherein said polynucleotide is DNA.
Claim 13
Independent Claim
30 words
The method of any of claims 1 to 11 wherein said polynucleotide directs transcription of a single RNA which is complementary or homologous to multiple sites within the retrovirus genome.
Claim 14
Independent Claim
29 words
The method according to any of claims 1 to 12, wherein said vector is selected from the group consisting of a viral vector, a retroviral vector and a plasmid.
Claim 15
Dependent Claim
11 words
The method of claim 13, wherein said vector is a plasmid.
Claim 16
Dependent Claim
21 words
The method of claim 14, wherein said plasmid is selected from the group of pUC19, pRSVcat, pSV2gpt, pSV2neo, pRSVneo and pRSVgpt.
Claim 17
Independent Claim
28 words
The method according to any of claims 1 to 15, wherein said vector further comprises a first promoter which controls transcription of said RNA within said host cell.
Claim 18
Independent Claim
30 words
The method according to any of claims 1 to 16, wherein said vector further comprises a first terminator which controls termination of transcription of said RNA within said host cell.
Claim 19
Independent Claim
22 words
The method according to any of claims 1 to 17, wherein said vector further comprises a marker for selection of transformed cells.
Claim 20
Independent Claim
28 words
The method according to any of claims 1 to 18, wherein said polynucleotide further comprises a second promoter which controls transcription of said RNA within said host cell.
Claim 21
Dependent Claim
14 words
The method according to claim 19, wherein said promoter is RNA Polymerase III promoter.
Claim 22
Independent Claim
30 words
The method according to any of claims 1 to 20, wherein said polynucleotide further comprises a second terminator which controls termination of transcription of said RNA within said host cell.
Claim 23
Dependent Claim
17 words
The method according to claim 21, wherein said second terminator is a RNA Polymerase III terminator sequence.
Claim 24
Independent Claim
44 words
The method according to any of claims 1 to 22, wherein said retrovirus is selected from the group consisting of human T-cell lymphotrophic virus, a human immunodeficiency virus, a lymphadenopathic virus, a leukemia virus, a sarcoma virus and a virus causing a lymphotrophic disease.
Claim 25
Independent Claim
33 words
The method according to any of claims 1 to 23, wherein said retrovirus is selected from the group consisting of HIV, feline leukemia virus, HTLV-I, HTLV-II, murine leukemia virus and avian leukemia virus.
Claim 26
Dependent Claim
13 words
The method according to claim 24, wherein said retrovirus is feline leukemia virus.
Claim 27
Dependent Claim
11 words
The method according to claim 24, wherein said retrovirus is HIV.
Claim 28
Dependent Claim
11 words
The method according to claim 24, wherein said retrovirus is HTLV-I.
Claim 29
Dependent Claim
80 words
RNA molecule which confers resistance to retrovirus infection, said RNA molecule transcribed within a host cell from a nucleic acid sequence introduced into said host cell by transformation with a vector, said nucleic acid sequence comprising a polynucleotide directing transcription of said RNA sequence, said RNA sequence (a) being complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) being effective to inhibit replication of said retrovirus.
Claim 30
Dependent Claim
80 words
RNA molecule which confers resistance to retrovirus infection, said RNA molecule transcribed within a host cell from a nucleic acid sequence introduced into said host cell by transformation with a vector, said nucleic acid sequence comprising a polynucleotide directing transcription of said RNA sequence, said RNA sequence (a) being complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) being effective to inhibit replication of said retrovirus.
Claim 31
Dependent Claim
69 words
RNA molecule according to claim 28, wherein said RNA sequence is complementary or homologous to a nucleic acid sequence within one or more regions within the genome of said retrovirus selected from the group consisting of the LTR region, the U5 region, the U3 region, the R region, the PBS region, the AUG start codon region, the polyP region, the cap site, the leader region and RNA splice sites.
Claim 32
Dependent Claim
30 words
RNA molecule according to any of claims 28 or 29, wherein said nucleic acid sequence comprising a polynucleotide directing transcription of said RNA sequence is a synthetic nucleic acid sequence.
Claim 33
Dependent Claim
17 words
RNA molecule according to any of claims 28 to 30, wherein said nucleic acid sequence is DNA.
Claim 34
Dependent Claim
26 words
RNA molecule according to any of claims 28 to 31, wherein said vector, polynucleotide and retrovirus are defined as in any of claims 12 to 27.
Claim 35
Dependent Claim
36 words
RNA molecule according to any of claims 28 to 32, wherein said nucleic acid sequence further comprises a polynucleotide directing transcription of a RNA sequence, said sequence redirecting reverse transcriptase enzyme in a nonfunctional transcription direction.
Claim 36
Dependent Claim
15 words
RNA molecule according to claim 33, wherein said RNA sequence is a False Template sequence.
Claim 37
Dependent Claim
15 words
RNA molecule according to claim 33, wherein said RNA sequence is a False Primer sequence.
Claim 38
Dependent Claim
67 words
Nucleic acid construct conferring resistance to retrovirus infection, said construct comprising a polynucleotide which when introduced into a host cell by transformation with a vector directs transcription within said host cell of RNA which (a) is complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) is effective to inhibit replication of said retrovirus.
Claim 39
Dependent Claim
67 words
Nucleic acid construct conferring resistance to retrovirus infection, said construct comprising a polynucleotide which when introduced into a host cell by transformation with a vector directs transcription within said host cell of RNA which (a) is complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) is effective to inhibit replication of said retrovirus.
Claim 40
Dependent Claim
69 words
Nucleic acid construct according to claim 36, wherein said RNA is complementary or homologous to a nucleic acid sequence within one or more regions within the genome of said retrovirus selected from the group consisting of the LTR region, the U5 region, the U3 region, the R region, the PBS region, the AUG start codon region, the polyP region, the cap site, the leader region and RNA splice sites.
Claim 41
Dependent Claim
27 words
Nucleic acid construct according to any of claims 36 or 37, wherein said vector, polynucleotide and retrovirus are defined as in any of claims 12 to 27.
Claim 42
Dependent Claim
73 words
Cell which has been transformed with a nucleic acid construct which conferrs resistance to retrovirus infection to said cell, said construct comprising a polynucleotide which when introduced into said cell by transformation directs transcription within said cell of RNA which (a) is complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) is effective to inhibit replication of said retrovirus.
Claim 43
Dependent Claim
73 words
Cell which has been transformed with a nucleic acid construct which conferrs resistance to retrovirus infection to said cell, said construct comprising a polynucleotide which when introduced into said cell by transformation directs transcription within said cell of RNA which (a) is complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) is effective to inhibit replication of said retrovirus.
Claim 44
Dependent Claim
67 words
Cell according to claim 39, wherein said RNA is complementary or homologous to a nucleic acid sequence in one or more regions within the genome of said retrovirus selected from the group consisting of the LTR region, the US region, the U3 region, the R region, the PBS region, the AUG start codon region, the polyP region, the cap site, the leader region and RNA splice sites.
Claim 45
Dependent Claim
25 words
Cell according to any of claims 39 to 40, wherein the vector, polynucleotide and retrovirus are defined as in any of claims 12 to 27.
Claim 46
Dependent Claim
97 words
The progeny of a cell which has been transformed with a nucleic acid construct which confers resistance to retrovirus infection to said progeny, said construct comprising a polynucleotide which when introduced into said cell by transformation directed transcription within said cell of RNA which (a) was complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) was effective to inhibit replication of said retrovirus, said progeny containing a sequence which is descendant from said polynucletide and is effective to inhibit replication of said retrovirus.
Claim 47
Dependent Claim
97 words
The progeny of a cell which has been transformed with a nucleic acid construct which confers resistance to retrovirus infection to said progeny, said construct comprising a polynucleotide which when introduced into said cell by transformation directed transcription within said cell of RNA which (a) was complementary or homologous to a nucleic acid sequence within one or more gene coding regions within the genome of said retrovirus and (b) was effective to inhibit replication of said retrovirus, said progeny containing a sequence which is descendant from said polynucletide and is effective to inhibit replication of said retrovirus.
Claim 48
Dependent Claim
71 words
Progeny of a cell according to claim 42, wherein said RNA was complementary or homologous to a nucleic acid sequence within one or more regions within the genome of said retrovirus selected from the group consisting of the LTR region, the U5 j region, the U3 region, the R region, the PBS region, the AUG start codon region, the polyP region, the cap site, the leader region and RNA splice sites.
Claim 49
Dependent Claim
28 words
Progeny of a cell according to any of claims 42 and 43, wherein the vector, polynucleotide and retrovirus are defined according to any of claims 12 to 27.
Claim 50
Dependent Claim
10 words
Progeny of any cell according to claims 39 to 41.
Claim 51
Dependent Claim
16 words
Cell and/or any progeny thereof according to any of claims 39 to 45 as a medicament.
Claim 52
Dependent Claim
23 words
Cell or any progeny thereof according to any of claims 39 to 45 as a medicament conferring resistance to retrovirus infection to cells.
Claim 53
Dependent Claim
49 words
Cell or any progeny thereof according to any of claims 39 to 35 as a medicament conferring resistance to infections of cells by retroviruses selected from the group consisting of human T-cell lymphotrophic virus, human immuodeficiency virus, lymphadenopathic virus, leukemia virus, sarcoma virus and virus causing a lymphotrophic disease.
Claim 54
Dependent Claim
23 words
Cell or any progeny thereof according to any of claims 39 to 45 as a medicament conferring resistance to HIV infection of cells.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.